These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 36398537)

  • 1. Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi-protein cascade of the complement system.
    Schmidt CQ; Smith RJH
    Immunol Rev; 2023 Jan; 313(1):376-401. PubMed ID: 36398537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
    Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and future pharmacologic complement inhibitors.
    Risitano AM
    Hematol Oncol Clin North Am; 2015 Jun; 29(3):561-82. PubMed ID: 26043392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
    Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
    Front Immunol; 2019; 10():1157. PubMed ID: 31258525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New Complement Therapeutics in Complement-Related Diseases].
    Wakamiya N; Ohtani K; Hidaka Y; Inoue N
    Brain Nerve; 2019 Jun; 71(6):555-564. PubMed ID: 31171752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Ariceta G
    Expert Rev Clin Pharmacol; 2023 May; 16(5):401-410. PubMed ID: 37128905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses.
    Nilsson PH; Thomas AM; Bergseth G; Gustavsen A; Volokhina EB; van den Heuvel LP; Barratt-Due A; Mollnes TE
    Mol Immunol; 2017 Sep; 89():111-114. PubMed ID: 28610663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Wong EK; Kavanagh D
    Transl Res; 2015 Feb; 165(2):306-20. PubMed ID: 25468487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics.
    Patriquin CJ; Kuo KHM
    Transfus Med Rev; 2019 Oct; 33(4):256-265. PubMed ID: 31703946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.
    Risitano AM; Marotta S
    Semin Immunol; 2016 Jun; 28(3):223-40. PubMed ID: 27346521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway.
    Schatz-Jakobsen JA; Zhang Y; Johnson K; Neill A; Sheridan D; Andersen GR
    J Immunol; 2016 Jul; 197(1):337-44. PubMed ID: 27194791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
    Risitano AM
    Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond.
    Gavriilaki E; de Latour RP; Risitano AM
    Blood; 2022 Jun; 139(25):3571-3582. PubMed ID: 34482398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic complement inhibition – from experimental to clinical medicine.
    Lappegård KT; Bjerre A; Tjønnfjord GE; Mollnes TE
    Tidsskr Nor Laegeforen; 2015 Oct; 135(19):1745-9. PubMed ID: 26486669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
    Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
    Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular pharmacology in complement-mediated hemolytic disorders.
    Bortolotti M; Barcellini W; Fattizzo B
    Eur J Haematol; 2023 Sep; 111(3):326-336. PubMed ID: 37308291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs that inhibit complement.
    Schrezenmeier H; Höchsmann B
    Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species.
    Zelek WM; Morgan BP
    Front Immunol; 2020; 11():612402. PubMed ID: 33424866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crovalimab: First Approval.
    Dhillon S
    Drugs; 2024 Jun; 84(6):707-716. PubMed ID: 38740735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan.
    Nishimura JI; Kawaguchi T; Ito S; Murai H; Shimono A; Matsuda T; Fukamizu Y; Akiyama H; Hayashi H; Nakano T; Maruyama S
    Int J Hematol; 2023 Oct; 118(4):419-431. PubMed ID: 37515657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.